Cardiovascular endocrinology & metabolism · 2025
BRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Kandanat Purushothaman Nair Suresh, Variam Manikandan Thiruvanath, S Bala Vignesh, Nath Kshitiz, Goyal Kailash Kumar, Beswal Gaurav, Arun Prashanth, Narayan Kiran, Kumar S P Sathish, Ravindranath V, Tripathy Nishant, Kalra Bharat Kumar, Ray Pranabes, Garg Pooja, Laul Anil, Dhand Sunil, Kamat Sajal, Kesarkar Rohan Narayan, Prasad Ashish, Pednekar Abhijit
Аннотация
BACKGROUND: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
AIM: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
METHODS: This was a retrospective, multicenter, observational study that included data from 168 T2DM patients with HF receiving treatment with FDC D/S. Outcome parameters included glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), hypertension, N-terminal pro-B-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), and adverse events.
RESULTS: The mean age of the patients was 55.5 ± 10.5 years. Most patients had comorbidities such as hypertension (86.3%) and dyslipidemia (75%), with more than 53% being obese. A significant (P < 0.0001) reduction was observed in HbA1c, FPG, PPG, and NT-proBNP levels, and in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 3 months of treatment with FDC D/S, while a significant (P < 0.0001) increase was observed in ejection fraction and eGFR, indicating improved glycemic control and heart function. Urinary tract infections (29.8%), dehydration (17.9%), hypoglycemia (14.9%), and genital mycotic infection (6.6%) were the common adverse events encountered with FDC D/S.
CONCLUSION: FDC D/S enhances glycemic control in T2DM patients with HF, leading to reductions in HbA1c, FPG, PPG, and cardiovascular risk factors such as NT-proBNP, SBP, and DBP, while also improving eGFR. The FDC D/S was generally well-tolerated, making it an effective and convenient treatment option.
AIM: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
METHODS: This was a retrospective, multicenter, observational study that included data from 168 T2DM patients with HF receiving treatment with FDC D/S. Outcome parameters included glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), hypertension, N-terminal pro-B-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), and adverse events.
RESULTS: The mean age of the patients was 55.5 ± 10.5 years. Most patients had comorbidities such as hypertension (86.3%) and dyslipidemia (75%), with more than 53% being obese. A significant (P < 0.0001) reduction was observed in HbA1c, FPG, PPG, and NT-proBNP levels, and in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 3 months of treatment with FDC D/S, while a significant (P < 0.0001) increase was observed in ejection fraction and eGFR, indicating improved glycemic control and heart function. Urinary tract infections (29.8%), dehydration (17.9%), hypoglycemia (14.9%), and genital mycotic infection (6.6%) were the common adverse events encountered with FDC D/S.
CONCLUSION: FDC D/S enhances glycemic control in T2DM patients with HF, leading to reductions in HbA1c, FPG, PPG, and cardiovascular risk factors such as NT-proBNP, SBP, and DBP, while also improving eGFR. The FDC D/S was generally well-tolerated, making it an effective and convenient treatment option.